Emergent BioSolutions, Inc., awarded $107 million BioThrax contract

Emergent BioSolutions, Inc., has received a new, $107 million contract from the Office of the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services to obtain regulatory approval for large-scale manufacturing of its anthrax vaccine BioThrax.

"In line with Emergent's mission of protecting life, we are proud to be working with HHS to scale-up manufacturing of BioThrax, the only vaccine licensed by the Food and Drug Administration for the prevention of anthrax infection," Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, Inc., said. "We applaud HHS for its unwavering commitment to strengthen the country's biodefense infrastructure and to protect our military and civilian populations."

The contract was awarded based on a technical proposal provided to BARDA by Emergent BioSolutions, Inc., that projected an annual large-scale manufacturing capacity of 26 million doses of BioThrax at the company's Building 55, Emergent BioSolutions, Inc.'s large-scale, state-of-the-art vaccine manufacturing facility in Lansing, Michigan.

Emergent BioSolutions, Inc., has developed a comprehensive plan that demonstrates comparability between the current manufacturing process and the large-scale manufacturing process for BioThrax.

The new contract is meant to fund activities related to process validation, assay validation and fill/finish. If needed, the contract will also fund non-clinical and clinical studies.